Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Price | Value | Graham Fair Value | Graham Fair Value % | P/E | Forward P/E | P/S | P/B | PEG | Free Cash Flow | Free Cash Flow Yield | Book Value | BVPS | EV | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LQDA | LIQUIDIA CORP | $58.75 | $18.62 | 215.53% | 244.77x | 17.72x | 17.95x | 48.11x | 1.16x | $41.15M | 0.80% | $108.58M | 1.23 | $5.18B | 96.75 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $295.63 | $95.94 | 208.14% | 67.81x | 40.09x | 9.16x | 36.70x | 1.39x | $641.34M | 1.63% | $1.08B | 8.09 | $40.73B | 44.06 | ||
| XERS | XERIS BIOPHARMA HOLDINGS INC | $6.07 | $2.88 | 111.05% | 86.71x | 50.79x | 3.29x | 80.54x | 0.83x | $47.52M | 4.60% | $13.01M | 0.08 | $1.19B | 22.36 | ||
| CORT | CORCEPT THERAPEUTICS INC | $70.44 | $19.19 | 267.07% | 153.13x | 134.53x | 9.57x | 11.85x | 1.44x | $119.79M | 1.63% | $637.99M | 6.11 | $7.46B | -1,086.91 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $48.43 | $17.64 | 174.55% | 49.42x | 37.93x | 4.91x | 6.15x | 1.34x | $164.23M | 4.43% | $605.69M | 7.92 | $3.55B | 31.80 | ||
| KRYS | KRYSTAL BIOTECH INC | $298.10 | $97.42 | 206.01% | 38.46x | 36.87x | 20.92x | 6.88x | 1.83x | $237.38M | 2.72% | $1.28B | 43.59 | $8.30B | 38.77 | ||
| ADMA | ADMA BIOLOGICS INC | $7.90 | $10.68 | -26.01% | 11.45x | 7.96x | 3.66x | 4.69x | 0.39x | $107.90M | 5.78% | $390.33M | 1.65 | $1.89B | 8.54 | ||
| OMER | OMEROS CORP | $10.72 | $15.81 | -32.20% | 8.25x | -28.15x | 77.68x | -12.25x | 0.42x | -$94.78M | -12.29% | -$63.33M | -0.88 | $1.08B | 11.99 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $55.03 | $41.58 | 32.34% | 39.31x | 13.85x | 3.27x | 1.71x | 0.55x | $767.06M | 7.24% | $6.21B | 32.27 | $8.99B | 18.64 | ||
| RPRX | ROYALTY PHARMA PLC | $55.18 | $40.62 | 35.86% | 28.89x | 10.35x | 9.88x | 3.20x | 0.62x | $2.34B | 9.71% | $9.94B | 22.75 | $40.14B | 34.51 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $11.49 | $16.56 | -30.62% | 5.60x | 24.45x | 5.49x | 3.30x | 0.71x | $56.42M | 8.41% | $205.80M | 3.52 | $584.78M | 4.04 | ||
| HALO | HALOZYME THERAPEUTICS INC | $68.14 | $71.81 | -5.11% | 23.02x | 8.23x | 5.34x | 36.80x | 0.42x | $667.65M | 8.29% | $219.64M | 1.86 | $9.91B | 15.89 | ||
| VCEL | VERICEL CORP | $32.82 | $9.30 | 252.74% | 76.33x | 68.08x | 5.70x | 4.70x | 1.61x | $47.49M | 2.85% | $356.23M | 7.02 | $1.66B | 41.10 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $229.78 | $97.45 | 135.80% | 29.09x | 25.50x | 16.64x | 4.62x | 1.43x | $122.22M | 2.68% | $997.32M | 50.16 | $4.94B | 21.91 | ||
| ASND | ASCENDIS PHARMA A | $218.82 | $85.31 | 156.49% | 23.19x | 17.62x | 13.34x | 23.67x | 2.16x | $52.94M | 0.39% | $574.09M | 9.24 | $13.97B | 149.83 | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $232.64 | $49.64 | 368.62% | 494.98x | 9.01x | 3.24x | 3.22x | 1.69x | $1.30B | 9.01% | $4.53B | 73.22 | $18.15B | 26.89 | ||
| SPRO | SPERO THERAPEUTICS INC | $2.83 | $5.84 | -51.54% | 10.48x | 4.14x | 2.65x | 3.10x | 0.22x | $7.24M | 4.45% | $52.93M | 0.92 | $110.21M | 7.11 | ||
| TECH | BIO-TECHNE CORP | $50.79 | $15.67 | 224.13% | 71.54x | 25.83x | 6.56x | 3.81x | 1.47x | $269.60M | 3.40% | $2.09B | 13.34 | $8.03B | 31.38 | ||
| TGTX | TG THERAPEUTICS INC | $37.41 | $18.96 | 97.28% | 11.62x | 24.93x | 7.71x | 9.82x | 7.60x | -$14.19M | -0.26% | $583.13M | 4.04 | $6.04B | 40.23 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $31.81 | $36.51 | -12.88% | 12.57x | 8.66x | 2.05x | 2.02x | 0.47x | $341.79M | 18.58% | $910.35M | 15.75 | $1.41B | 5.95 | ||
| UTHR | UNITED THERAPEUTICS CORP | $544.62 | $251.89 | 116.21% | 18.60x | 18.74x | 7.47x | 3.92x | 1.97x | $1.02B | 4.29% | $5.90B | 135.66 | $21.84B | 12.74 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $438.40 | $172.85 | 153.63% | 25.77x | 22.41x | 9.12x | 5.75x | 1.84x | $3.71B | 3.33% | $19.36B | 76.20 | $107.76B | 19.98 | ||
| NAGE | NIAGEN BIOSCIENCE INC | $3.61 | $2.50 | 44.13% | 15.04x | 15.26x | 2.21x | 3.49x | 1.02x | $4.11M | 1.41% | $82.33M | 1.03 | $223.54M | 10.52 | ||
| EXEL | EXELIXIS INC | $50.28 | $31.41 | 60.07% | 16.12x | 15.26x | 5.47x | 6.53x | 1.17x | $917.69M | 7.06% | $1.94B | 7.49 | $12.58B | 11.91 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $31.27 | $15.17 | 106.11% | 17.28x | 16.26x | 6.40x | 3.78x | 1.96x | $208.13M | 5.44% | $1.01B | 8.28 | $3.07B | 9.18 | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $2.06 | $1.77 | 16.16% | 10.84x | 9.48x | 2.15x | 2.47x | 0.94x | $13.00M | 7.91% | $67.23M | 0.84 | $132.75M | 5.95 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $600.66 | $451.01 | 33.18% | 14.11x | 12.70x | 4.19x | 2.00x | 0.92x | $4.11B | 6.58% | $31.42B | 302.15 | $62.72B | 10.92 | ||
| VCYT | VERACYTE INC | $48.18 | $12.57 | 283.44% | 43.41x | 42.81x | 7.07x | 2.86x | 2.49x | $155.34M | 4.05% | $1.34B | 16.90 | $3.62B | 31.46 | ||
| SRPT | SAREPTA THERAPEUTICS INC | $17.61 | $4.69 | 275.88% | 29.35x | 5.05x | 0.85x | 1.24x | 4.11x | $109.24M | 5.91% | $1.51B | 14.34 | $2.43B | 29.39 | ||
| INCY | INCYTE CORP | $95.59 | $67.36 | 41.91% | 13.11x | 12.14x | 3.55x | 3.40x | 1.16x | $1.45B | 7.61% | $5.62B | 28.21 | $15.67B | 8.37 | ||
| MDXG | MIMEDX GROUP INC | $3.58 | $1.59 | 125.13% | 17.05x | -50.14x | 1.36x | 2.19x | 2.64x | $69.36M | 13.04% | $242.94M | 1.64 | $391.05M | 7.18 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.